안티센스 올리고뉴클레오티드 시장 : 제품 유형별, 용도별, 치료 용도별, 지역별

Antisense Oligonucleotides Market is estimated to be valued at USD 2.48 billion in 2026 and is expected to reach USD 6.05 billion by 2033, growing at a compound annual growth rate (CAGR) of 13.6% from 2026 to 2033.

The global antisense oligonucleotides market covers a broad set of product type categories, including Modified Antisense Oligonucleotides, Unmodified Antisense Oligonucleotides, and Gapmers, used across applications such as Oncology, Neurological Disorders, and Infectious Diseases. Demand is supported by adoption among Rare Genetic Disorders, and Chronic Diseases and the need for more efficient, reliable solutions. Continued technological advancement and rising end-user requirements are shaping the growth of this market.

Market Dynamics:

Growing adoption across Oncology, and Neurological Disorders, rising end-user demand, and a continued focus on improving efficiency and performance are major factors expected to drive growth of the global antisense oligonucleotides market. A wider range of available options is making these solutions accessible to a broader base of users.

For instance, companies are expanding their portfolios to address evolving requirements across Rare Genetic Disorders, and Chronic Diseases. Moreover, increasing investment in innovation and new technology integration is expected to create new growth opportunities for market players over the forecast period.

Key features of the study:

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global antisense oligonucleotides market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Ionis Pharmaceuticals, Sarepta Therapeutics, Alnylam Pharmaceuticals, Biogen, Pfizer, Novartis, Akcea Therapeutics, Wave Life Sciences, Dyne Therapeutics, and ProQR Therapeutics, among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global antisense oligonucleotides market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antisense oligonucleotides market.

Detailed Segmentation:

• Global Antisense Oligonucleotides Market, By Product Type (Revenue, USD Bn, 2021 - 2033)
• Modified Antisense Oligonucleotides
• Unmodified Antisense Oligonucleotides
• Gapmers
• Mixmers
• Others
• Global Antisense Oligonucleotides Market, By Application (Revenue, USD Bn, 2021 - 2033)
• Oncology
• Neurological Disorders
• Infectious Diseases
• Cardiovascular Diseases
• Others
• Global Antisense Oligonucleotides Market, By Therapeutic Use (Revenue, USD Bn, 2021 - 2033)
• Rare Genetic Disorders
• Chronic Diseases
• Infectious Diseases
• Drug Delivery Systems
• Regional Insights (Revenue, USD Bn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Company Profiles:
• Ionis Pharmaceuticals*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
• Sarepta Therapeutics
• Alnylam Pharmaceuticals
• Biogen
• Pfizer
• Novartis
• Akcea Therapeutics
• Wave Life Sciences
• Dyne Therapeutics
• ProQR Therapeutics

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Preview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Product Type
  • Market Snapshot, By Application
  • Market Snapshot, By Therapeutic Type
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Recent Product Launches
• Epidemiology
• Merger, Acquisition, and Collaboration
• Regulatory Scenario
• Key Developments
• PEST Analysis
• Partnership Scenario
• Brand and Pricing Analysis
• Distributors Landscape
• Porters Analysis
• Technological Advancements
• Key Developments
• Market Trend
• Future Prospective
• Top Market Players by Revenue

4. Antisense Oligonucleotides Market By Product Type, 2026-2033, (US$ Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• Modified Antisense Oligonucleotides
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
• Unmodified Antisense Oligonucleotides
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
• Gapmixer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
• Mixmers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)

5. Antisense Oligonucleotides Market By Application, 2026 - 2033, (US$ Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• Oncology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
• Neurological Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
• Infectious Diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
• Cardiovascular Diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)

6. Antisense Oligonucleotides Market By Therapeutic Type, 2026 - 2033, (US$ Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• Rare Genetic Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
• Chronic Diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
• Infectious Diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
• Drug Delivery Systems
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)

7. Antisense Oligonucleotides Market By Region, 2026 - 2033, (US$ Billion)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2022-2033
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Type, 2026 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Type, 2026 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Type, 2026 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Benelux
    • Denmark
    • Norway
    • Sweden
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Type, 2026 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
    • China
    • Taiwan
    • India
    • Japan
    • Indonesia
    • Malaysia
    • Philippines
    • Singapore
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East & Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Type, 2026 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
• Bahrain
• Kuwait
• Oman
• Qatar
• Saudi Arabia
• UAE
• Israel
• South Africa
• North Africa
• Central Africa
• Rest of the Middle East

1. Competitive Landscape

• Ionis Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Sarepta Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Alnylam Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Biogen
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Pfizer
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Novartis
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Akcea Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Wave Life Sciences
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Dyne Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• ProQR Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

2. Section

• Research Methodology
• About Us